학술논문
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial
Document Type
Article
Author
Source
In: British Journal of Dermatology . (British Journal of Dermatology, November 2023, 189(5):531-539)
Subject
Language
English
ISSN
13652133
00070963
00070963